Parametric mapping using spectral analysis for11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects by Fan, Z et al.
ORIGINAL ARTICLE
Parametric mapping using spectral analysis for 11C-PBR28 PET reveals
neuroinflammation in mild cognitive impairment subjects
Zhen Fan1 & Melanie Dani1 & Grazia D. Femminella1 & Melanie Wood1 & Valeria Calsolaro1 & Mattia Veronese2 &
Federico Turkheimer2 & Steve Gentleman1 & David J. Brooks1,3 & Rainer Hinz4 & Paul Edison1
Received: 12 October 2017 /Accepted: 19 February 2018
# The Author(s) 2018. This article is an open access publication
Abstract
Purpose Neuroinflammation and microglial activation play an important role in amnestic mild cognitive impairment (MCI) and
Alzheimer’s disease. In this study, we investigated the spatial distribution of neuroinflammation in MCI subjects, using spectral
analysis (SA) to generate parametricmaps and quantify 11C–PBR28 PET, and compared these with compartmental and other kinetic
models of quantification.
Methods Thirteen MCI and nine healthy controls were enrolled in this study. Subjects underwent 11C–PBR28 PET scans with
arterial cannulation. Spectral analysis with an arterial plasma input function was used to generate 11C–PBR28 parametric
maps. These maps were then compared with regional 11C–PBR28 VT (volume of distribution) using a two-tissue compartment
model and Logan graphic analysis. Amyloid load was also assessed with 18F–Flutemetamol PET.
Results With SA, three component peaks were identified in addition to blood volume. The 11C–PBR28 impulse response
function (IRF) at 90 min produced the lowest coefficient of variation. Single-subject analysis using this IRF demonstrated
microglial activation in five out of seven amyloid-positive MCI subjects. IRF parametric maps of 11C–PBR28 uptake revealed
a group-wise significant increase in neuroinflammation in amyloid-positive MCI subjects versus HC in multiple cortical asso-
ciation areas, and particularly in the temporal lobe. Interestingly, compartmental analysis detected group-wise increase in 11C–
PBR28 binding in the thalamus of amyloid-positive MCI subjects, while Logan parametric maps did not perform well.
Conclusions This study demonstrates for the first time that spectral analysis can be used to generate parametric maps of 11C–
PBR28 uptake, and is able to detect microglial activation in amyloid-positiveMCI subjects. IRF parametric maps of 11C–PBR28
uptake allow voxel-wise single-subject analysis and could be used to evaluate microglial activation in individual subjects.
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Introduction
Amnestic mild cognitive impairment (MCI) is a transitional
stage between preclinical Alzheimer’s disease and dementia.
Microglial activation plays a significant role in Alzheimer’s
disease, along with amyloid and tau deposition [1–3]. Recent
PET imaging studies have suggested that microglial activation
correlates closely with the severity of dementia [1, 4, 5].
However, imaging microglia has been challenging. The 18-
kDa translocator protein (TSPO) is a cholesterol-transporter
protein expressed in the outer mitochondrial membrane of
microglial cells and astrocytes in the brain. TSPO expression
in normal brain is very low, but it increases significantly after
trauma and inflammation [6–8]. The PET tracer 11C–R-
PK11195 PET has been used for over 20 years to assess the
level of TSPO expression and microglial activation [9–11].
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However, 11C–R-PK11195 has a poor signal-to-noise ratio [6,
12]. In an attempt to improve the signal-to-noise ratio, several
second-generation TSPO radioligands have been developed.
The new-generation TSPO tracers are affected by genetic var-
iability of TSPO binding site induced by the rs6971 single-
nucleotide polymorphism [13], and recent studies have dem-
onstrated that tracer signal in the high-affinity binders (HAB)
is 25–35% higher than in the mixed affinity binders (MAB)
[14, 15]. However, our group has previously demonstrated
that results gathered from a TSPO subgroup (HAB or MAB)
can be translated to the entire AD and MCI population [16].
11C–PBR28 is a second-generation TSPO PET tracer, and
can be used to quantify microglial activation in neurodegen-
erative disease; however, recent studies have demonstrated
discordant results in neuroinflammation in AD or MCI sub-
jects using 11C–PBR28 PET imaging [5, 17–19]. In fact, the
quantification of TSPO is challenging; the tracer binds not
only to microglia (and to a lesser extent to astrocytes) in the
parenchyma but also to the endothelium and smooth muscle
cells [20–22]. Since endothelial TSPO is physically in contact
with plasma, its apparent affinity for radioligands is higher
than parenchymal TSPO.
Spectral analysis (SA) is a powerful kinetic tool for gener-
ating parametric maps of ligand volumes of distribution from
brain TACs with a plasma input function. As a spectral tech-
nique, it makes no assumptions about kinetic compartments,
but identifies heterogeneous kinetic components which repre-
sent tracer delivery, vascular binding, and later parenchymal
tracer-binding components [22, 23].
In this study, for the first time, we performed spectral anal-
ysis on 11C–PBR28 PET dynamic images to generate para-
metric maps of ligand uptake reflected by area under impulse
response function (IRF). We compared the SA parametric
mapping to the compartmental models and the parametric
mapping using Logan graphic analysis. Finally, we evaluated
microglial activation between two cohorts (MCI vs HC) using
11C–PBR28 SA parametric mapping, LoganVTand two tissue
compartment models, with a view to identify the most appro-




Thirteen MCI patients and nine age-matched healthy controls
(all genetically high binders for TSPO ligands— HAB) were
recruited from memory clinics and the Join Dementia
Research website. This study was approved by the local and
regional regulatory ethics committee (London Riverside
Research Ethics Committee - National Health Research
Services, Health Research Authority, UK), and the approval
for administration of radioactivity was given by ARSAC
(Administration of Radioactive Substances Advisory
Committee).
Image acquisition
MRI scans were acquired for all subjects with a 3 Tesla
SIEMENS 32-channel Verio MRI scanner (MPRAGE; time
repetition = 2400 ms, time echo = 3.06 ms, flip angle of 9,
inversion time = 900 ms, matrix = 256 × 246). The T1 images
were used for co-registration of the PET for ROI analysis,
while T2-weighted images were used to exclude any signifi-
cant white matter microvascular disease.
All subjects underwent 11C–PBR28 PET scans with a
SIEMENS Biograph TruePoint PET/CT scanner (axial field =
21.8 cm, transaxial planes =111, and spatial resolution =
2.056 mm × 2.056 mm × 2 mm) at Imanova, London. A
low-dose CT scan was performed for attenuation correction,
followed by injection of a mean activity of 300 MBq 11C–
PBR28 intravenously. A continuous 3D dynamic acquisition
was performed in list mode for 90 min. The dynamic 11C–
PBR28 PET data were reconstructed using scatter correction,
attenuation correction and random correction. Then the data
were corrected for decay and rebinned as 26 time frames.
Twenty-one subjects (12 MCI and 9 HC) also had 18F–
Flutemetamol PET scans using a Siemens Biograph 6 PET/CT
scanner. A mean activity of 182 (±2.5) MBq 18F–
Flutemetamol was injected intravenously. PET data were ac-
quired 90–120 min after the injection to generate a static 3D
18F–Flutemetamol PET image. The cerebellum was used as
the reference region to create the 18F–Flutemetamol RATIO
image as previously described [24].
Blood data
All patients had continuous online blood sampling for the first
15 min after the 11C–PBR28 PET scan started, and 12 discrete
blood samples were taken at 5, 10, 15, 20, 25, 30, 40, 50, 60,
70, 80, and 90 min, allowing blood and plasma radiotracer
activity to be measured. The time course of 11C–PBR28 ac-
tivity in the plasma was calculated with a linear model fit
using plasma-to-blood ratio model in the first 15 min of online
whole-blood data. Parent tracer and metabolite levels were
measured using HPLC analysis for discrete blood samples.
A sigmoid model was applied to describe the parent fraction
of 11C–PBR28, which was then used to generate the parent
fraction of plasma input function.
Quantification of 11C–PBR28 PET using spectral
analysis
Spectral analysis applies a positively constrained general lin-
ear model to fit the tissue kinetics with a large matrix of
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exponential functions with a range of decaying factors convo-
luted with the plasma input function [25]. The solution to each
fit is a vector of linear coefficients αi (peak height), each
corresponding to a decay βi (peak position), and is obtained
using non-negative least squares (NNLS) [23, 26]. In the so-
lution vector, the non-zero coefficients for the high-frequency
components (e.g., large βi) usually reflect the dynamics of the
tracer in the blood; the ones with slower βi reflect the kinetics
of reversible parenchymal perfusion between plasma or tissue
compartments, while the slowest components represent irre-
versible trapping. The beta-min was used as the decay con-
stant of the 11C (0.00056629) for 11C–PBR28. The tissue
11C–PBR28 ligand-binding response could be measured as
portion of impulse response function (IRF), which was
reflected by the sum of the intermediate and low frequency
components of the spectrum. In this study, we generated
IRF(t) parametric maps with different epochs of observation-
time: 30 min, 45 min, 60 min, 75 min, and 90 min for 11C–
PBR28 using the formula:




where t represents the selected observation time, n denotes
number of PET time frames, αi and βi are the peak height
and peak position for time frame i.We used a decay constant λ
of 0.00056629 for 11C–PBR28. In order to provide a high
quality IRF(t) parametric maps, the coefficient of variation
(CV) (standard deviation/mean) of 11C–PBR28 binding in
major cortices (frontal, temporal, parietal, and occipital lobe)
and thalamuswere calculated at different observation time; the
lower CV indicated a higher precision and lower noise level
for that IRF(t) parametric map. (Online Resource 1A).
Quantification of 11C–PBR28 PET using
compartmental modelling
Compartmental modelling of TACs was performed to deter-
mine the volumes of distribution of the 11C–PBR28 tracer
using the parent plasma input function and dynamic PET ac-
quisition. In this study, we fitted kinetic data to two compart-
mental models for 11C–PBR28 [21, 27]: the two-tissue com-
partmental model (2TCM4k), and the two-tissue compart-
mental model with an extra vascular component (2TCM4k-
1 K), which accounts for the extra binding compartment for
the endothelial cells of blood vessels [21, 28]. We calculated
the Akaike information criterion (AIC) to evaluate the model
performance [29, 30]. The model with lower AIC was chosen
as the preferred model for a predefined ROI. Total volume of
distribution (VT), rate constant (k), and binding potential
(BPND) were the parameters derived from the kinetic models
usingMICK software (modelling input function compartmental
kinetics) and MATLAB2014a.
Quantification of 11C–PBR28 PET using Logan graphic
analysis
Logan analysis is a graphical quantification method which
linearises PET uptake data using a plasma or non-specific
tissue reference input function where ligands bind reversibly.
The gradients of fits represent VT and can be used for para-
metric mapping at a voxel level, though measurement noise is
also linearised and a potential confound. Logan graphic anal-
ysis is independent of the number of compartments as long as
they are all in equilibrium after a time t. The 11C–PBR28
Logan VT parametric map was generated, where VT reflects
the slope of the linear section of the Logan graphic plot [31].
Logan graphical analysis was performed using MICK para-
metric mapping software developed in MATLAB2014a. CV
was measured in major cortices and thalamus to assess the
signal variation for the Logan VT.
Region of interest (ROI) analysis in MCI and HC
Regional quantification of mean 11C–PBR28 binding was es-
timated for compartmental model VT, SA parametric map
(IRF) and Logan VT map in MCI and healthy controls. To
evaluate the binding, MRI and brain atlas (83-region
Hammersmith atlas) were spatially transformed into native
PET space using SPM8, and Analyze 11.0 (AnalyzeDirect)
was used to sample the regional mean tracer update in
predefined ROI regions as described in our previous studies.
The ROI regional mean uptake was sampled in the following
regions: posterior cingulate, frontal, temporal, parietal, and
occipital lobes. ROI analysis was also performed for medial
temporal lobe, hippocampus, and thalamus. The regional ROI
value was regarded as significantly raised (positive) for that
region when it is elevated more than 2SD above the mean of
healthy controls. The MCI subjects were considered as 11C–
PBR28 positive when at least one cortical region was positive.
Voxel-level analysis between MCI and HC
The parametric maps generated by SA or Logan graphic anal-
ysis allowed us to perform voxel-wise comparisons between
patients and healthy controls. 1) Parametric maps were co-
registered to their corresponding MRIs, 2) normalization and
smoothing (6 mm× 6 mm× 6 mm) were applied to the co-
registered PET to generate the individual normalized PET in
SPM8, and 3) each patient’s normalized parametric map was
then compared against a group of controls to generate a single-
subject SPM T-map at voxel level, which localised significant
pathological increases in each patient. The significant cluster
threshold was set at p < 0.05 with an extent threshold of 50
voxels. Family-wise error rate (FWE) was corrected for mul-
tiple comparisons. For each subject who had significant clus-
ters of increased 11C–PBR28, those clusters were extracted as
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individual VOI (volume of interest) maps, and the total vol-
ume of VOI was calculated in mm3 in Analyze 11.0.
Brain amyloid status
As the MCI cohorts are heterogeneous, the brain amyloid
status for each subject was evaluated from 18F–flutemetamol
RATIO images. In this study, an amyloid-positive subject was
defined as having uptake in at least one of the large cortices or
two separate cortical regions higher than the mean + 2SD of
healthy controls.
Statistics
Group mean and standard deviation were calculated in
SPSS23 (SPSS, Chicago, IL, USA), for each diagnostic
group, and Student’s t-test was used to interrogate significant
increases in the tracer uptake. The Pearson correlation coeffi-
cient was applied to measure the degree of linear correlation
between two groups of variables using SPSS23, and a p-value
of < 0.05 was regarded as a significant correlation.
Results
Demographics
The demographic details of 13 MCI and 9 control subjects
(aged 54–79 yrs) are detailed in the Online Resource 1B. The
MCI coho r t d emons t r a t ed s i gn i f i c an t l y l owe r
neuropsychometric test scores compared to the age-matched
healthy controls.
Brain amyloid status
18F–Flutemetamol scans were performed for 12 MCI and
9 HC subjects. Seven of the 12 MCI subjects had signifi-
cantly higher amyloid deposition than healthy controls in mul-
tiple brain regions, and were classified as amyloid-positive.
Spectral analysis
We identified three peaks along with fractional blood volume
of 0.065 (± 0.013) in spectra (Fig. 1a). The high-frequency
kinetic spectral component probably corresponded to the vas-
cular TSPO (see Turkheimer et al., 2007 [20]) while the other
two probably represented free and bound tracer in parenchy-
ma. The tissue IRF(t) curve is equivalent to the sum of three
spectral component peaks (Fig. 1b). Given different sets of
observation time for generating IRF parametric map, IRF at
90 min (IRF-90) demonstrated the lowest noise level with
global CV mean of 18% (SD = 4%).
The 11C–PBR28 IRF parametric map (Fig. 2) generated by
spectral analysis provided the opportunity to evaluate each
patient for neuroinflammation at a voxel level. In this study,
the single-subject analysis detected seven MCI patients (five
amyloid-positive and two amyloid-negative) who had signif-
icant clusters of elevated microglial activation in frontal gyrus,
temporal lobe, parietal gyrus, anterior cingulate gyrus, occip-
ital lobe and in thalamus compared to the healthy control
cohort (Fig. 3 and Online Resource 2). Furthermore, VOI
analyses were performed on those seven MCIs who had sig-
nificantly increased 11C–PBR28, which measured volumes of
significantly increased 11C–PBR28 binding ranging from
114,982 to 714,801mm3 (Table 1).
In the ROI analysis, parametric mapping of 11C–PBR28
IRF revealed a group-wise significant increase in neuroin-
flammation in the temporal lobe and multiple other brain
Fig. 1 a Kinetic spectrum for a healthy control subject, which revealed
three different components [at position βi of 7.07e-04 s-1 (blue), 1.58e-
03 s-1 (green) and 5.01e-03 s-1 (red) with amplitude αi of 8.35e-04 s-1,
1.03e-03 s-1, and 1.21e-03 s-1] with fractional blood volume (bv) of
0.065 (cyan). b Predicted curves using spectral analysis IRF (impulse
response function) for tracer activity (dashed line) which was measured
by the sum of three individual components of the spectrum. The blue (KI),
green and red curves corresponded to the three component peaks in the
spectrum
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regions in the amyloid-positive MCI subjects compared to
healthy controls (Table 2). Individually, four amyloid-
positive MCIs and two amyloid-negative MCIs revealed
ROIs with higher binding than mean + 2SD of healthy
controls.
Compartmental modelling
The parent plasma fraction and the plasma:blood ratio of 11C–
PBR28 over 90 min are shown in Fig. 4. The 2TCM4k-1 K
(AIC = −84) compared with the 2TCM4k model (AIC = −76)
provided a marginally better fit of 11C–PBR28 PET uptake
data (Online Resource 3). This is consistent with previous
studies [21, 32]. VT derived from 2TCM4k-1 K and
2TCM4k correlated well with a Pearson correlation coeffi-
cient around 0.7 (p < 0.0001) (Fig. 5).
Compartmental VT demonstrated a group-wise increase in
thalamus (31%, p < 0.037) and left MTL (32%, p < 0.05) in
11C–PBR28 VT in amyloid-positive MCI subjects compared
to the controls. Individually, 4/7 of amyloid-positive MCI
subjects showed increased uptake in 11C–PBR28 VT com-
pared to the controls, while one amyloid-negativeMCI subject
demonstrated an increase in 11C–PBR28 VT. Both compart-
mental models, 2TCM4k-1 K VT and 2TCM4k VTwere pos-
itively correlated with the 11C–PBR28 binding in IRF paramet-
ric maps (Fig. 5). A Pearson correlation was performed to
assess the relationship between 11C–PBR28 IRF-90 and
BPND (k3/k4), and a positive correlation was found in frontal
lobe (r = 0.55, p = 0.01), temporal lobe (r = 0.7, p < 0.0001),
Fig. 2 Individual IRF-90 and
Logan VT parametric maps
demonstrated with corresponding
MR image. Upper panel displays
an MCI patient, middle panel
shows a healthy control (HC), and
lower panel demonstrates the
group-wise average image
(Mean) and standard deviation
image (SD). The colour bar on
the left represents the colour scale
used for IRF-90 images, and the
colour bar on the right represents
the colour scale used for Logan
VT images
Fig. 3 Single-subject VOI analysis of IRF. The colour map represents the
significant clusters of increased 11C–PBR28 binding for eachMCI patient
compared to healthy control cohort. Aβ+ and Aβ- represent amyloid-
positive MCI and amyloid-negative MCI subjects respectively. The
colour bar indicates the significant Z-score which was used for the
colour-coded map
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parietal lobe (r = 0.76, p < 0.0001), and occipital lobe (
r = 0.57, p = 0.007). (Online Resource 4).
Logan graphic analysis
Based on linear fit of the whole brain 11C–PBR28 uptake and
parent plasma input function, dynamic data from 2000 to
5400 s (six data points) were selected to generate Logan plot
(slope = 3.8 ± 0.09 and intercept = −3033 ± 214) to create
Logan VT parametric map. Logan VT resulted in a higher
CV compared to IRF-90 parametric maps in different cortices
(Fig. 2 and Online Resource 1A). With the VOI analysis,
Logan maps localised a volume range of 108,237 to
423,979 mm3 containing increased neuroinflammation in in-
dividuals (Table 1). At a voxel level, single-subject analysis of
11C–PBR28 Logan parametric VT maps revealed three
amyloid-positive MCI subjects and one amyloid-negative
MCI subject who had neuroinflammation in anterior cingu-
late, frontal gyrus, temporal gyrus, parietal lobe, and occipital
lobe compared with healthy controls.
A good correlation was found between IRF-90 and Logan
parametric maps of 11C–PBR28 (Fig. 5). However, Logan
parametric maps failed to localise clusters of significantly
raised mean 11C–PBR28 uptake at the group level.
Individually, ROI analysis revealed two amyloid-positive
and one amyloid-negative MCI subjects with a higher level
of 11C–PBR28 binding compared with mean + 2SD of healthy
controls.
Discussion
For the first time, we have demonstrated that spectral analysis
can be used reliably to quantify 11C–PBR28 PET. 11C–PBR28
PET tracer has 80-fold higher affinity for TSPO compared to
previous tracers developed to evaluate microglial activation;
however, different methodological approaches used in differ-
ent studies have produced varying results [5, 14, 15, 33, 34].
As TSPO distribution has a heterogeneous cellular distribu-
tion with endothelial, smooth muscle, and parenchymal com-
ponents all exhibiting different kinetic behaviour, in this study
we evaluated the feasibility of generating 11C–PBR28 para-
metric map using spectral analysis. IRF-90 parametric map-
ping of 11C–PBR28 correlated well with Logan VT and VT
generated by compartment models. Compared to compart-
mental analysis, the IRF-90 parametric maps provided model
free quantification and enable comparison between subjects or
Table 2 11C–PBR28 ROI group
results of IRF-90 mean and
standard deviation in amyloid
positiveMCI subjects and healthy
controls
Healthy control Amyloid-positive MCIs
Mean SD Mean SD P value %
Frontal lobe 0.00037 0.00008 0.00045 0.00008 0.074 19%
Temporal lobe 0.00039 0.00006 0.00048 0.00008 0.010* 25%
Parietal lobe 0.00035 0.00006 0.00041 0.00010 0.115 16%
Occipital lobe 0.00036 0.00005 0.00041 0.00011 0.136 14%
Post-cingulate 0.00037 0.00008 0.00048 0.00011 0.025* 31%
Thalamus 0.00045 0.00007 0.00057 0.00014 0.024* 29%
Striatum 0.00037 0.00008 0.00040 0.00008 0.220 10%
Brainstem 0.00053 0.00005 0.00062 0.00012 0.060 16%
MTL 0.00042 0.00005 0.00053 0.00008 0.005* 27%
Hippocampus 0.00044 0.00005 0.00054 0.00010 0.019* 22%
Amygdala 0.00044 0.00006 0.00057 0.00008 0.003* 29%
Fusiform 0.00040 0.00006 0.00053 0.00010 0.009 32%
Cerebellum 0.00037 0.00007 0.00047 0.00010 0.023* 27%
Whole brain 0.00037 0.00006 0.00045 0.00009 0.049* 20%
*P< 0.05; MTL=medial temporal lobe; SD= Standard deviation
Table 1 The volume of significant 11C–PBR28 increase in single
subject using 11C–PBR28 parametric mapping of IRF and Logan
graphic analysis
Subject Increased 11C–PBR28 volume (mm3)
IRF Logan
MCI 1 191,073 \
MCI 2 714,801 423,979
MCI 3 114,982 \
MCI 4 260,442 165,193
MCI 5 177,119 \
MCI 6 360,328 289,142
MCI 7 373,282 108,237
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between regions at a voxel level. Compared with Logan VT
maps, 11C–PBR28 IRF-90 parametric maps showed a lower
noise level. IRF parametric mapping of 11C–PBR28 was able
to reveal group-wise significant microglial activation in
amyloid-positive MCI subjects across multiple brain regions.
On an individual basis, IRF-90 parametric maps revealed
microglial activation in individuals who had significant amy-
loid deposition.
As vascular binding can interfere with quantification of
parenchymal binding of TSPO tracers [35], spectral analysis
[22, 23] has the advantage of separating the high-frequency
component which represents tracer binding in the vasculature.
SA identifies two tissue components, and another low fre-
quency component which is suggestive of an additional irre-
versible vascular trapping component to 11C–PBR28 kinetics.
Interestingly this is in agreement with the spectral analysis
application to 11C–PK11195 [20]. The time-course of changes
in 11C–PBR28 IRF is reflected by the sum of low and
intermediate frequency components in the spectrum. In this
study, we have demonstrated that 90 min is optimal for gen-
erating IRF parametric mapping of 11C–PBR28.
It has now been established that TSPO binding is quite
heterogeneous within a given area in brain. It is also sug-
gested that TSPO could be expressed in microglia, endothelial
cells, and there is a debate about the expression in astrocytes.
Some studies have demonstrated that there is irreversible
binding to the vascular endothelium, while there is reversible
binding to the brain tissue. This gives rise to heterogeneous
kinetics of both reversible and irreversible components.
Spectral analysis does not make any a-priori assumptions
about whether a tracer is reversible or irreversible, and pro-
vides optimal parametric map at the pixel level [22, 26]. In the
spectrum, each tissue compartment is displayed as a spectral
component with an amplitude (α) and a frequency (β). The
impulse response function generated by the convolution of
these components for 11C–PBR28 PET indicates the response
Fig. 5 a The correlation between 11C–PBR28 IRF-90 and Logan VT in
frontal lobe and temporal lobe. b The correlation between 11C–PBR28
IRF and 2TCM4k-1 K VT in frontal lobe and temporal lobe. c The
correlation between 11C–PBR28 IRF and 2TCM4k VT in frontal lobe
and temporal lobe. d The correlation between 2TCM4k-1 K VT and
2TCM4k VT in frontal lobe and temporal lobe
Fig. 4 11C–PBR28 blood data. a Parent fraction in arterial plasma. b Plasma over blood ratio
Eur J Nucl Med Mol Imaging
of the brain tissue in response to the injected TSPO tracer. This
could be quantified using a complex mathematical model as
described below. A spectral analysis allows us to quantify
the tissue response throughout the whole cortex without
any a-priori assumption. Additionally, it allows us to
quantify the tracer uptake in an individual subject. There
is extensive evidence in brain imaging and molecular bi-
ology studies, which have demonstrated that in-vivo brain
amyloid deposition is closely correlated with microglial
activation in AD and MCI subjects [36–38]. Okello
et al. reported that MCI patients with higher amyloid de-
position had significantly higher mean levels of cortical
microglial activation [39]. In our study, seven MCIs have
been classified as amyloid-positive subjects using 18F–
flutemetamol PET. Compared to other modelling
methods, IRF parametric mapping of 11C–PBR28 has re-
vealed a more extensive profile of neuroinflammation in
amyloid-positive MCIs, with a 19–27% group increase
across temporal lobe and multiple cortical regions.
Compartmental analysis only demonstrated group-wise in-
creased 11C–PBR28 in the amyloid-positive group in the
thalamus, while Logan parametric maps failed to localise
any significant increase at the group level.
Considering the heterogeneity of neuroinflammation in
MCIs, it is crucial for researchers to assess the neuroinflam-
mation on an individual basis rather than as a group. In this
study, 11C–PBR28 IRF parametric mapping demonstrated a
larger total volume of significantly increased 11C–PBR28, es-
pecially for MCI subjects who had amyloid plaques, consis-
tent with the neuropathological findings. Interestingly, one
amyloid-positive MCI subject, who revealed a significant
cluster of increased microglial activation when IRF and
Logan parametric maps were interrogated at a voxel level,
was negative with an 11C–PBR28 ROI analysis.
While one of the limitations of the current study is that only
MCI subjects have been assessed, we are aiming to recruit
established AD patients to further validate the IRF parametric
mapping strategy for 11C–PBR28 PET. Despite that, we have
previously demonstrated that results gathered from a TSPO
subgroup (HAB or MAB) can be translated to an entire AD
and MCI population [16]. Another limitation is only HAB
cases have been included; our group is recruiting more partic-
ipants in order to evaluate the performance of 11C–PBR28 IRF
in mixed binding affinity groups. SA is highly sensitive and is
performed using arterial input analysis, which is the most
robust quantitative method of analysis. Small variation could
lead to bias in data estimation; however, the arterial blood
acquisition and modelling in this study were carefully per-
formed. Nevertheless, this preliminary report has revealed
powerful evidence that parametric mapping of 11C–PBR28
using spectral analysis which separates the endothelial com-
ponent provides a high-quality whole-brain map which could
be used to analyze MCI subjects on an individual basis.
Conclusion
In this study, we have demonstrated that spectral analysis can
be used to generate 11C–PBR28 parametric maps. We have
identified a high-frequency blood volume peak and three other
spectral peaks which represent a slow irreversible trapping
component and two tissue components. Results demonstrated
11C–PBR28 parametric maps generated by spectral analysis
had a signal-to-noise ratio large enough to evaluate the
microglial activation at voxel level on an individual basis. In
conclusion, we have demonstrated, for the first time, that IRF
parametric map generated by spectral analysis can reliably be
used in quantifying 11C–PBR28 PET to assess neuroinflam-
mation in prodromal Alzheimer’s disease.
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